Imatinib 800 mg: Preliminary results of a phase II trial of the GIMEMA CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high sokal risk patients. | AVESİS

Ankara University Research Information System

Imatinib 800 mg: Preliminary results of a phase II trial of the GIMEMA CML working party in intermediate sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high sokal risk patients.

Copy For Citation

Rosti G., Martinelli G., Castagnetti F., Testoni N., Specchia G., Bassan R., ...More

47th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 10 - 13 December 2005, vol.106, (Summary Text)

Publication Type: Conference Paper / Summary Text
Volume: 106
City: Georgia
Country: United States Of America
Ankara University Affiliated: No